247 related articles for article (PubMed ID: 22570330)
1. Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
Wardell SE; Kazmin D; McDonnell DP
Mol Endocrinol; 2012 Jul; 26(7):1235-48. PubMed ID: 22570330
[TBL] [Abstract][Full Text] [Related]
2. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
Liu S; Han SJ; Smith CL
Mol Pharmacol; 2013 May; 83(5):1066-77. PubMed ID: 23462505
[TBL] [Abstract][Full Text] [Related]
3. Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.
DuSell CD; Nelson ER; Wittmann BM; Fretz JA; Kazmin D; Thomas RS; Pike JW; McDonnell DP
Mol Endocrinol; 2010 Jan; 24(1):33-46. PubMed ID: 19901195
[TBL] [Abstract][Full Text] [Related]
4. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
5. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
Wardell SE; Nelson ER; McDonnell DP
Steroids; 2014 Nov; 90():30-8. PubMed ID: 25084324
[TBL] [Abstract][Full Text] [Related]
6. Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol.
Nelson ER
Methods Mol Biol; 2016; 1366():431-443. PubMed ID: 26585155
[TBL] [Abstract][Full Text] [Related]
7. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.
DuSell CD; Umetani M; Shaul PW; Mangelsdorf DJ; McDonnell DP
Mol Endocrinol; 2008 Jan; 22(1):65-77. PubMed ID: 17872378
[TBL] [Abstract][Full Text] [Related]
8. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
[TBL] [Abstract][Full Text] [Related]
9. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling.
Soulez M; Parker MG
J Mol Endocrinol; 2001 Dec; 27(3):259-74. PubMed ID: 11719280
[TBL] [Abstract][Full Text] [Related]
11. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells.
Frasor J; Stossi F; Danes JM; Komm B; Lyttle CR; Katzenellenbogen BS
Cancer Res; 2004 Feb; 64(4):1522-33. PubMed ID: 14973112
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
[TBL] [Abstract][Full Text] [Related]
14. Differential utilization of nuclear and extranuclear receptor signaling pathways in the actions of estrogens, SERMs, and a tissue-selective estrogen complex (TSEC).
Madak-Erdogan Z; Gong P; Katzenellenbogen BS
J Steroid Biochem Mol Biol; 2016 Apr; 158():198-206. PubMed ID: 26689478
[TBL] [Abstract][Full Text] [Related]
15. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7.
Diel P; Olff S; Schmidt S; Michna H
Planta Med; 2001 Aug; 67(6):510-4. PubMed ID: 11509969
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
18. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
19. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.
Wardell SE; Nelson ER; Chao CA; McDonnell DP
Clin Cancer Res; 2013 May; 19(9):2420-31. PubMed ID: 23536434
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]